3ª Edição

Diandrogalactitol overcomes temozolomide resistance mechanisms in glioblastoma

por: Grupo Oncoclínicas
Diandrogalactitol overcomes temozolomide resistance mechanisms in glioblastoma

Comissão científica

Carolina Fittipaldi
Carolina Fittipaldi
Fabiana Viola
Fabiana Viola
Roberto Abramof
Roberto Abramof

Colaboradores

Daniele Ferreira Neves
Daniele Ferreira Neves
Mirela Souto Brito
Mirela Souto Brito

One of the main obstacles in the treatment of glioblastoma (GBM) is resistance to chemotherapy. “There is a wide spectrum of tumor cell resistance to currently available therapies, involving different mechanisms, such as resistance to apoptosis, drug efflux and induction of DNA repair. It is known that patients with high expression of MGMT are resistant to temozolamide”, comments clinical oncologist Mirela Souto Brito, from the Oncology Nucleus of Bahia – Grupo Oncoclínicas. In this context, identifying and overcoming the mechanisms underlying it is fundamental for the development of new therapeutic approaches.

An article published in the journal Molecular Cancer Therapeutics analyzed the combination of temozolomide, a first-line treatment for these patients, and dianhydrogalactitol, which is being tested in clinical trials for GBM and already has its use approved for the treatment of other tumors. According to Daniele Ferreira Neves, clinical oncologist at the Oncoclínicas Group, Ipanema Unit, this study showed the benefits of combining the two drugs in the treatment of these tumors. “The study speculates and proves (in vitro) that the drugs used together can synergistically reduce the proliferation of tumor cells, which also reduces the possibility of the emergence of resistance. The benefit occurs in both GBM with MGMT methylation and in GBM without methylation.”

Access our website and read the full article with all the details of this study.

Acesse o artigo completo deste estudo
Download
Compartilhe
Ou compartilhe o link
Link copiado para sua área de trabalho.L